NRx Pharmaceuticals, Inc. Stock News

In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.

NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.

NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript

RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will re

NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Tuesday after the clinical-stage pharmaceutical company announced a proposed public offering for its shares. We still don't know the finer deta

The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more t

We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giv

As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk.

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Off

RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonatha

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen W

RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen W